Gene editing technology could treat Hepatitis B
A gene editing technology has shown promising early results in treating patients with Hepatitis B.
Participants in the ELIMINATE-B trial were dosed in PBGENE-HBV, developed by gene editing company Precision BioSciences, at multiple ascending dose levels.
Results show PBGENE-HBV, which comprises an ARCUS-encoding mRNA encapsulated in a lipid nanoparticle (LNP), was safe and well tolerated in all three participants with chronic Hepatitis B who are HBeAg-negative after the first administration of a 0.2 mg/kg dose.
PBGENE-HBV also demonstrated a substantial reduction in Hepatitis B surface antigen (HBsAg) in two of the three participants following the first dose administration.
“This exciting initial safety data set provides evidence that ARCUS encapsulated in a LNP was well tolerated in chronic Hepatitis B patients upon first dose administration at dose level 1,” said Murray Abramson, Head of Clinical Development at Precision BioSciences.
“When studying novel technologies and drug mechanisms it is important to monitor safety closely, and we believe the extensive preclinical safety experiments Precision conducted along with several rounds of mRNA optimisation were critical steps to ensure patient safety.”
“These data excite the entire Precision team, and we hope it instils confidence among the patients who are courageously embarking in our clinical trial,” added Michael Amoroso, President and Chief Executive Officer of Precision BioSciences.
“Progress against this wide-spread and devastating disease would not be possible without their participation. This marks an important step forward for Precision in a large patient population and the second clinical validation of ARCUS in vivo gene editing following the recent clinical data from the OTC-HOPE study being conducted by our partner iECURE in a dire rare disease.”
